Synthetic Design Lab

- 24/04/2025
- Unknown
- $20,000,000
A next-generation ADC company developing a novel SYNTHBODY therapeutic platform against a range of cancer types
- Industry Biotechnology Research
- Website https://www.syntheticdesignlab.com/
- LinkedIn https://www.linkedin.com/company/synthetic-design-lab-inc/
Related People
Daniel Chen, M.D. Ph.D.Founder

Author of The Cancer-Immunity Cycle (Immunity 2013) and the Cancer-Immune Set Point (Nature 2017) with Ira Mellman.
A pioneer in the field of Cancer Immunotherapy, emergence of PD-L1/PD-1 inhibitors and next generation therapies. Focused on the future of medicine and what's possible at the intersection between engineering, science and medicine.
Experienced drug developer (from pre-clinical through Phase I-IV), entrepreneur, executive- strong communicator and strategic leader with expertise in Oncology, Immunology, Large Molecule Engineering, Virology, Filings, Biomarkers and Building/Leading Organizations.